パーキンソン病 - KOLの見識

当レポートでは、パーキンソン病の治療について調査分析し、KOLへのインタビューから得られた見識に基づき、既存の治療薬とパイプライン治療薬の有効性、課題、可能性に焦点を当て、パーキンソン病の現在と将来の治療情勢に関する詳細な情報を提供しています。

企業

目次

エグゼクティブサマリー

現在と将来の治療アルゴリズム

調査目的

パーキンソン病の現在の治療慣行とアンメットニーズ

パーキンソン病治療の新たな方向性

承認された治療法

• ドーパミン作動薬
• 固定用量配合剤（FDC）
• MAO-B阻害薬
• COMT阻害薬
• その他の薬剤

パイプライン治療法

• ドーパミン作動薬
  • Aplindore（DAB 452、Seelos Therapeutics）
  • Tavapadon（AbbVie/Cerevel Therapeutics）
• FDC治療法
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612（levodopa + carbidopa subcutaneous infusion、NeuroDerm/Mitsubishi Tanabe Pharma）
  • P2B001（pramipexole + rasagiline、Pharma Two B）
• その他の作用機序
  • Nabilone FDT（AOP Orphan Pharmaceuticals）
  • Mesdopetam（Integrative Research Laboratories）
  • Buntanetap（R-phenserine/Posiphen、Annovis Bio）
• 早期段階の医薬品候補
  • Alpha-synuclein inhibitors
  • UCB0599（UCB）
  • PRX002（prasinezumab、Roche）
  • ENT-01（kenterin、Enterin）
  • ION464（Ionis Pharma/Biogen）
  • Radotinib（Il-Yang Pharm. Co.）
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• その他の作用機序/パイプライン候補

将来の治療パラダイム

付録

Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.

Key questions answered:

• What treatments currently form the backbone of Parkinson's Disease therapy?
• What are the advantages and disadvantages of these treatments?
• What are the current unmet needs and challenges in treating Parkinson's Disease?
• Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
• Do any of the current pipeline therapies address unmet treatment needs?
• How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?

Key brands covered in this report:

• Alpha-synuclein inhibitors (e.g. cinpanemab, ENT-01, ION464, prasinezumab, UCB0599)
• Buntanetap ((+)(3aR)phenserine)
• Cell/gene therapies and various other early-stage MOAs
• Comtan (entacapone)
• DNL151
• Dostinex (cabergoline)
• Duopa (levodopa/carbidopa intraduodenal)
• IPX203 (carbidopa/levodopa)
• Mesdopetam
• Ongentys (opicapone)
• P2B-001 (pramipexole/rasagiline)
• PRODUODOPA/VYALEV (foscarbidopa/foslevadopa)
• Repurposed drugs (e.g. nilotinib, GLP-1 agonists (exenatide sustained-release, liraglutide, lixisenatide NLY01), etc.)
• Requip franchise (ropinirole/ER)
• Rytary (levodopa/carbidopa ER)
• Stalevo (levodopa/carbidopa/entacapone)

Companies:

Table of Contents

Executive summary

• This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:

Current and future treatment algorithm

Research objectives

Current treatment practice and unmet needs in Parkinson's disease

• Key insights summary
  • First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience

New directions in Parkinson's disease therapy

• Key insights summary
  • Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine

Approved therapies

• Dopamine agonists
  • Key insights summary
• Fixed-dose combination (FDC) agents
  • Key insights summary
• MAO-B inhibitors
  • Key insights summary
• COMT inhibitors
  • Key insights summary
• Other agents
  • Key insights summary

Pipeline therapies

• Dopamine agonists
  • Aplindore (DAB 452; Seelos Therapeutics)
  • Tavapadon (AbbVie/Cerevel Therapeutics)
• FDC therapies
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001 (pramipexole + rasagiline; Pharma Two B)
• Other modes of action
  • Nabilone FDT (AOP Orphan Pharmaceuticals)
  • Mesdopetam (Integrative Research Laboratories)
  • Buntanetap (R-phenserine/Posiphen; Annovis Bio)
• Early-phase drug candidates
  • Alpha-synuclein inhibitors
  • UCB0599 (UCB)
  • PRX002 (prasinezumab; Roche)
  • ENT-01 (kenterin; Enterin)
  • ION464 (Ionis Pharma/Biogen)
  • Radotinib (Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• Other mechanisms of action/pipeline candidates
  • Key insights summary

Future treatment paradigm

• Key insights summary
  • Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe